Yes. Welcome, everybody, to our Q3 report presentation. As usual, Stefan and I will go through what has happened during that time period. Stefan will cover the financials. I will handle the rest. And without any further ado, I will start the presentation with our forward-looking statement.
I would like to start with a quick summary. What has happened? Events in the third quarter, as well as the events after the end of the period.
And obviously, one very important event during the third quarter was our prior authorization in the portfolio to really focus on the two lead programs, with all the resources doubling down on the two most advanced programs, BI-1808 and BI-1206.
And I will come back with a little bit more detail later.
And then the other thing was that there was a change in the board. Vincent Ossipow, who has been with us for many years.
Stepped down for priority reasons. And I think this is a very normal change. And as I said, he has been with us for almost ten years. Following the end of the period, the most important event was the initiation of the Phase IIa trial for 1206 in advanced or metastatic non-small cell lung cancer and uveal melanoma. And this is a first-line study.
So, it's extremely exciting.
So this is based on the promising data that we have generated in heavily pretreated patients.
We showed that data to Merck, and they agreed that we could proceed with the combination trial in first-line non-small cell lung cancer and uveal melanoma. It's extremely exciting.
Then, we had some data presentations. So the phase one clinical data for BI-1910, our TNFR2 agonist for the treatment of solid tumors. It will be presented at CDC in 2025. And then together with Transgene, we presented translational data and updated clinical results on the armed oncolytic virus program BT-001.
That was at ESMO this year.
So coming back to our prioritization, what you see here on this slide is the portfolio.
And that's still our portfolio. So what we're doing now, of course, is prioritizing the two lead programs. That makes a lot of sense because 1808 and 1206 are now in advanced clinical studies, which means they are in phase two. These are two assets that are active in both liquid and solid tumors, and they are first in class. And the other program. So 1910, our second TNFR2 program, as well as 1607.
Our second NT FcγRIIB program. They are now paused, and then the BT-001 program in solid tumors, which is basically the oncolytic virus containing our anti-CTLA-4 antibody, is continued.
Based on investigator-initiated trials. We're really now focusing and doubling down on 1808 and 1206.
And on this slide, you have the summary of what I have partly already said.
In August 2025, we announced the decision to focus on our two most advanced programs, BI-1206 and BI-1808.
And what I always say, this is obviously an unfair competition, because 1910 and 1607 might also be interesting, but they're much, much earlier. They're still in phase one dose escalation. And of course, 1206 and 1808 are already in phase two. The earlier clinical programs, as I already have said, will be paused after a wind-down period to complete the ongoing trial activities because we want to pause it in a way that we can reuse it either ourselves or with a partner. And also the underlying research activities are now streamlined to better support the two lead clinical programs.
1206 and, uh, 1808. So this slide would show you the prioritized portfolio, where we have basically 1808 and 1206, as I already said.
So, 1808 is our TNFR2 program, which is running as a single agent as well as in combination with pembrolizumab in solid tumors and T-cell lymphomas.
And both. 1206, our lead entity FcγRIIB program, is running in combination for non-Hodgkin lymphoma with rituximab and acalabrutinib.
And in solid tumors with pembrolizumab.
It's already been mentioned that this trial has been initiated, focusing on first-line non-small cell lung cancer and uveal melanoma. Just for completeness, on the right-hand side of this slide, you see our partners. Whenever we use Pembro, we do so under a supply and collaboration agreement with Merck.
Uh, and whenever we use Acalabrutinib, this is under a similar agreement with AstraZeneca.
And that is something very interesting because those are two potential partners that are already sitting at the table in a way. And then, of course, the last name is our longstanding partner in China, CASI. They have exclusive rights for the BI-1206 program in China, Hong Kong, Macau, and Taiwan.
So, more detailed information around the programs, just to recap where we stand. As I already mentioned, BI-1808 is developed for T-cell lymphoma as well as solid tumors, both as a single agent and in combination.
Here on this slide, we present the data from June this year. Basically, the monotherapy is showing really promising strong efficacy in CTCL and PTCL. We had 100% disease control in nine evaluable patients, with complete responses, partial responses, and stable disease.
And of course, it's important to remember or to remind everybody that these patients are heavily, heavily pretreated.
But we also have on top of that two evaluable patients in CTCL, which is an even more severe form of T-cell lymphoma, where we had one partial response and one patient with stable disease.
It's important to note that the treatment is well tolerated with only mild to moderate adverse events. So basically, no toxicity issues. And also, very importantly, immune activation was observed. It was observed early on, with depletion of regulatory T cells and the influx of CD8 positive T cells into the skin lesions, which is very, very important.
And then to remind everybody, we have orphan drug designation for PTCL and fast track designation for CTCL.
So what is next?
This will be actual additional data already this year. Additional phase two data. I think we guided the market that this will come next year, but we have good progress and we will already have an update this year. Then going into the other parts of the 1808 program, which is the solid tumor study.
We have established single-agent activity, which is really something exciting because antibodies against TIGIT or LAG3 have never achieved that. We observed complete responses, partial responses, and actually had 11 out of 26 evaluable patients showing a response. And obviously, again, we have very, very heavily pretreated patients.
And again, I emphasize this is single-agent activity with a very good safety profile. And then what we also presented at ASCO in June 2024 is some initial activity or data that we had in the combination, which of course was a little bit later since we started the single agent clinical development first and then followed on with the combination with Pembrolizumab. And here we have already guided the market.
So the phase two pembrolizumab combination data in solid tumors. That will also be a first data point or second data point, actually, after the ASCO in 2024 for this year. So basically for BI-1808, there will be an update on monotherapy for CTCL. And as promised, we will provide the update on the combination with pembrolizumab in solid tumors this year. Then I switch to our anti-FcγRIIB program with BI-1206 that we developed in non-Hodgkin's lymphoma and solid tumors, starting with the data that we presented this year. That is the combination with acalabrutinib and rituximab. We had 100% disease control in the first eight patients out of 30 patients in the complete trial. Complete responses, partial responses, and stable disease demonstrate a good overall response rate. And again, this treatment has been well-tolerated with no safety and tolerability concerns. And of course, it's important to note that BI-1206 is administered subcutaneously. This means we have a very convenient and safe profile for this combination, making it a highly competitive option in the evolving non-Hodgkin lymphoma treatment landscape. We have orphan drug designation.
And also here we have an update because we guided the market that we will come out with the next data set during the first half of next year. And that will already happen this year. So, it is also very exciting, which means this is already the third update. That will be in addition to what we had already guided the market for. On the other hand, regarding the solid cancer study, you might remember the very strong data we have shown, targeting patients who no longer respond to anti-PD-1 or anti-PD-L1 therapies, and who have received two or more immuno-oncology treatments. Two or more I-O treatments. And we saw complete responses and partial responses. We showed that data to Merck, and they agreed that we can move into the first line. And that's what we have already started.
So there was a press release a week or two weeks ago, and we're focusing on advanced metastatic non-small cell lung cancer and uveal melanoma.
And we're focusing on sites in Georgia, Germany, Poland, Romania, Spain, Sweden, and the US.
And here, as we have already guided the market.
So we will have a first glimpse of the data during the second half of next year.
Then very briefly on CTLA-4, even though that is not our core focus, but it is worth mentioning since it happened. So that was presented at ESMO.
We could show that the BT-001 injection combination with pembrolizumab was well tolerated, showing positive local abscopal and sustained anti-tumoral activity in injected and non-injected lesions.
Long-lasting partial responses were observed, and the overall data supports further development across a range of solid tumors.
Tumor types to improve responses to cancer immunotherapies.
And the next step here is the evaluation of BT-001 via the investigator-led trial in an early-stage setting. What I already have mentioned, and then I hand over to Stefan for the financial overview.